{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lung+Disease&page=23",
    "query": {
      "condition": "Chronic Lung Disease",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 2098,
    "total_pages": 210,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lung+Disease&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lung+Disease&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T06:59:17.222Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00862641",
      "title": "A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma",
        "Coronary Artery Disease",
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Regadenoson",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1009,
      "start_date": "2009-04",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2012-09-18",
      "last_synced_at": "2026-10-15T06:59:17.222Z",
      "location_count": 48,
      "location_summary": "Montgomery, Alabama • Anaheim, California • Encinitas, California + 43 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00862641"
    },
    {
      "nct_id": "NCT03240575",
      "title": "The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Olodaterol",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone propionate",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2017-08-14",
      "completion_date": "2019-05-06",
      "has_results": true,
      "last_update_posted_date": "2020-04-16",
      "last_synced_at": "2026-10-15T06:59:17.222Z",
      "location_count": 45,
      "location_summary": "Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03240575"
    },
    {
      "nct_id": "NCT02197975",
      "title": "Randomized, Crossover Safety and Pharmacokinetics Study of PT010",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "PT010 Dose 1",
          "type": "DRUG"
        },
        {
          "name": "PT010 Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-08",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2014-10-28",
      "last_synced_at": "2026-10-15T06:59:17.222Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02197975"
    },
    {
      "nct_id": "NCT01126437",
      "title": "Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "tiotropium 18 mcg",
          "type": "DRUG"
        },
        {
          "name": "tiotropium 1.25 mcg (2 actuations/day)",
          "type": "DRUG"
        },
        {
          "name": "tiotropium 2.5 mcg (2 actuations/day)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 17183,
      "start_date": "2010-05",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-06-20",
      "last_synced_at": "2026-10-15T06:59:17.222Z",
      "location_count": 303,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01126437"
    },
    {
      "nct_id": "NCT05127304",
      "title": "A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Trelegy Ellipta",
          "type": "DEVICE"
        },
        {
          "name": "Stiolto Respimat",
          "type": "DEVICE"
        },
        {
          "name": "Furoate/Umeclidinium/Vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium Bromide/Olodaterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 11316,
      "start_date": "2021-02-26",
      "completion_date": "2022-02-03",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-10-15T06:59:17.222Z",
      "location_count": 1,
      "location_summary": "Eden Prairie, Minnesota",
      "locations": [
        {
          "city": "Eden Prairie",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127304"
    },
    {
      "nct_id": "NCT07744425",
      "title": "Shortwave Infrared Surgical Imaging Device Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cholecystitis",
        "Cholecystitis, Chronic",
        "Chronic Calculous Cholecystitis",
        "Primary Hyperparathyroidism",
        "Sigmoid Colon Diverticulitis",
        "Multinodular Goiter",
        "Thyroid and Parathyroid Surgery"
      ],
      "interventions": [
        {
          "name": "Observational study of SWIR imaging device in surgery",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cision Vision, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-05-29",
      "completion_date": "2026-10-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-15T06:59:17.222Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Evanston, Illinois • Glenview, Illinois + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Glenview",
          "state": "Illinois"
        },
        {
          "city": "Highland Park",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07744425"
    },
    {
      "nct_id": "NCT03337620",
      "title": "Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Headache, Migraine"
      ],
      "interventions": [
        {
          "name": "Tx360",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Tian Medical Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 174,
      "start_date": "2017-09-20",
      "completion_date": "2023-12-29",
      "has_results": false,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-10-15T06:59:17.222Z",
      "location_count": 11,
      "location_summary": "New Haven, Connecticut • Stamford, Connecticut • Fort Gordon, Georgia + 8 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Fort Gordon",
          "state": "Georgia"
        },
        {
          "city": "Chalmette",
          "state": "Louisiana"
        },
        {
          "city": "Watertown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03337620"
    },
    {
      "nct_id": "NCT02663518",
      "title": "A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematologic Malignancies",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PF-0791800 (TTI-621)",
          "type": "DRUG"
        },
        {
          "name": "PF-07901800 (TTI-621) plus Rituximab",
          "type": "DRUG"
        },
        {
          "name": "PF-07901800 (TTI-621) plus Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 249,
      "start_date": "2016-01-28",
      "completion_date": "2022-11-23",
      "has_results": true,
      "last_update_posted_date": "2024-05-10",
      "last_synced_at": "2026-10-15T06:59:17.222Z",
      "location_count": 47,
      "location_summary": "Duarte, California • Palo Alto, California • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02663518"
    },
    {
      "nct_id": "NCT03531489",
      "title": "Study of Ambulatory Respiratory Assist Device in Chronic Obstructive Pulmonary Disease Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COPD",
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "AIR-AD",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Right-Air",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-04-26",
      "completion_date": "2018-12-30",
      "has_results": false,
      "last_update_posted_date": "2018-05-21",
      "last_synced_at": "2026-10-15T06:59:17.222Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03531489"
    },
    {
      "nct_id": "NCT02838108",
      "title": "The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)",
        "Emphysema",
        "Chronic Bronchitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 452,
      "start_date": "2016-10",
      "completion_date": "2018-04-19",
      "has_results": false,
      "last_update_posted_date": "2019-10-29",
      "last_synced_at": "2026-10-15T06:59:17.222Z",
      "location_count": 1,
      "location_summary": "Kannapolis, North Carolina",
      "locations": [
        {
          "city": "Kannapolis",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02838108"
    }
  ]
}